Sign in
Active, not recruitingNo phase

Guo's Subclavian Artery Reconstruction: The Prospective, Multiple Center Study of WeFlow-Tbranch Stent Graft System(GUEST Study)

Key facts

Who runs it
Hangzhou Endonom Medtech Co., Ltd.
Where
China29 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
120 people enrolled
Started
25 Dec 2020
Expected to end
25 Dec 2026
Type of study
Interventional
Treatments tested
  • WeFlow-Tbranch Stent Graft System
Record updated
30 April 2024

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Patients aged 18 to 80 years old, no gender limitation
  • Able to understand the purpose of the trial, participate in the trial voluntarily with informed consent form signed by the patient him/herself or his or her legal representative, and willing to complete follow-up visits as required under the protocol
  • Diagnosed as Stanford type B aortic dissection and needed reconstruction of the left subclavian artery
  • The diameter of the proximal anchoring area (the aorta at the posterior edge of the left common carotid artery) range: 18~42mm
  • The length of the proximal anchoring area (the distance from the rear edge of the left common carotid artery opening to the first breach) ≥15mm
  • The distance between the left common carotid artery and the left subclavian artery ≥5mm
  • The distance between the left vertebral artery and the opening of the left subclavian artery is ≥15mm, the diameter of the starting part of the left subclavian artery is 6~20mm
  • With proper femoral artery, iliac artery, and brachial artery access, endovascular treatment of the aorta can be performed

Who cannot take part

  • Participated in clinical trials of other drugs or devices during the same period
  • Contraindications to antiplatelet drugs and anticoagulants
  • The same operation requires intervention in other vascular diseases (such as coronary artery, renal artery, superior mesenteric artery, etc.), and the postoperative drug treatment plan is therefore affected
  • Allergic to contrast agents, anesthetics, patches, and delivery materials
  • History of myocardial infarction, TIA or cerebral infarction within the past 3 months
  • Life expectancy is less than 12 months (such as advanced malignant tumors)
  • Acute systemic infection
  • Severe liver, kidney, lung, and heart function abnormalities before surgery [Serum creatinine exceeds 2 times the upper limit of normal; Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeds 5 times the upper limit of normal; Serum total bilirubin (STB) more than 2 times the upper limit of normal; Left ventricular ejection fraction is lower than normal by cardiac color Doppler ultrasound examination]
  • Pregnant, breastfeeding or cannot contraception during the trial period
  • Cannot tolerate anesthesia
  • True/false thoracic aortic aneurysm
  • Severe stenosis or calcification in the anchoring area at the proximal end of the stent, easily lead to the stent graft difficult adherent
  • Investigator judged that not suitable for interventional treatment

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is a prospective, multiple center study to evaluate the safety and effectiveness of WeFlow-Tbranch single embedded branch thoracic aorta stent graft system manufactured by EndoNom Medtech (Hangzhou) Co., Ltd.

The group in the trial

  • WeFlow-Tbranch Stent Graft SystemTreatment being tested

    Participants will be treated with WeFlow-Tbranch Stent Graft System

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
30 April 2024